Last 7 days
-1.4%
Last 30 days
8.5%
Last 90 days
3.3%
Trailing 12 Months
-8.5%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-08-31 | Geary Richard S | acquired | 30.5575 | 30.5575 | 1.00 | officer level 14 |
2023-08-31 | Monia Brett P | acquired | 4,797 | 30.5575 | 157 | ceo level 15 |
2023-08-31 | BENNETT C FRANK | acquired | 5,500 | 30.5575 | 180 | officer level 14 |
2023-08-01 | Diaz Allene M. | sold | -26,969 | 41.05 | -657 | - |
2023-07-18 | KLEIN JOSEPH III | sold | -149,310 | 42.00 | -3,555 | - |
2023-07-17 | BERTHELSEN SPENCER R | acquired | - | - | 7,110 | - |
2023-07-17 | Hayden Michael R | acquired | - | - | 7,110 | - |
2023-07-17 | Diaz Allene M. | acquired | - | - | 5,333 | - |
2023-07-17 | LOSCALZO JOSEPH | acquired | - | - | 7,110 | - |
2023-07-17 | KLEIN JOSEPH III | acquired | - | - | 7,110 | - |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | added | 58.33 | 4,559 | 10,134 | -% |
2023-09-06 | Deep Track Capital, LP | unchanged | - | 14,992,200 | 116,282,000 | 5.38% |
2023-08-24 | Alberta Investment Management Corp | sold off | -100 | -3,624,960 | - | -% |
2023-08-23 | Stonebridge Capital Advisors LLC | new | - | 2,831 | 2,831 | -% |
2023-08-22 | COMERICA BANK | new | - | 6,000 | 6,000 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 51.09 | 601,192 | 1,419,640 | 0.01% |
2023-08-21 | BOKF, NA | reduced | -2.51 | 256,784 | 2,410,510 | 0.05% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.53 | 702,215 | 6,605,750 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -8.12 | 18,593 | 359,559 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 8.79 | 2,792,740 | 14,009,700 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Jun 09, 2023 | vanguard group inc | 10.07% | 14,414,917 | SC 13G/A | |
Feb 14, 2023 | bb biotech ag | 6.8% | 9,635,000 | SC 13G/A | |
Feb 14, 2023 | t. rowe price investment management, inc. | 8.2% | 11,678,259 | SC 13G | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.54% | 13,546,694 | SC 13G/A | |
Feb 01, 2023 | blackrock inc. | 6.5% | 9,182,911 | SC 13G/A | |
Apr 11, 2022 | price t rowe associates inc /md/ | 10.1% | 14,350,460 | SC 13G/A | |
Feb 14, 2022 | price t rowe associates inc /md/ | 8.8% | 12,490,280 | SC 13G/A | |
Feb 11, 2022 | bb biotech ag | 7.2% | 10,232,973 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 8.50% | 12,007,076 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 05, 2023 | 4 | Insider Trading | |
Sep 05, 2023 | 4 | Insider Trading | |
Sep 05, 2023 | 4 | Insider Trading | |
Aug 23, 2023 | 8-K | Current Report | |
Aug 22, 2023 | 8-K | Current Report | |
Aug 14, 2023 | 144/A | 144/A | |
Aug 11, 2023 | S-8 | Employee Benefits Plan | |
Aug 09, 2023 | 8-K | Current Report | |
Aug 09, 2023 | 10-Q | Quarterly Report | |
Aug 04, 2023 | 8-K | Current Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABBV | 271.4B | 56.0B | 2.30% | 9.45% | 31.25 | 4.84 | -2.31% | -31.27% |
BGNE | 265.4B | 1.8B | -1.67% | 25.43% | -153.19 | 146.56 | 69.45% | 14.65% |
VRTX | 90.8B | 9.5B | 0.45% | 22.78% | 26.99 | 9.56 | 13.83% | 5.33% |
REGN | 89.0B | 12.7B | -1.51% | 18.09% | 20.7 | 7.02 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -7.00% | -17.21% | -20.61 | 17.72 | 39.94% | -8.44% |
SRPT | 11.0B | 1.0B | 3.70% | 3.57% | -12.12 | 10.97 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.05 | 4.98 | 18.01% | 38.16% |
MID-CAP | ||||||||
BPMC | 3.1B | 225.6M | 0.04% | -28.00% | -5.53 | 13.59 | -2.11% | 21.02% |
MDGL | 3.0B | - | -10.01% | 147.80% | -9.03 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.59 | 6.42 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -14.18% | -57.07% | -2.57 | 69.63 | - | -14.43% |
SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.23 | 4.28 | 77.72% | 112.02% |
MGNX | 281.2M | 152.5M | -11.67% | 38.41% | 37.75 | 1.84 | 127.84% | 103.41% |
CRBP | 29.9M | - | 1.35% | 3552.08% | -0.65 | - | - | -31.51% |
2.7%
-2.8%
-6.1%
90%
55%
21.1%
Y-axis is the maximum loss one would have experienced if Ionis Pharmaceuticals was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | 9.5% | 630,591,000 | 575,971,000 | 587,367,000 | 875,483,000 | 848,809,000 | 840,768,000 | 810,456,000 | 660,731,000 | 687,717,000 | 707,504,000 | 729,264,000 | 932,664,000 | 940,477,000 | 958,753,000 | 1,122,599,000 | 821,034,000 | 798,537,000 | 752,471,000 | 599,674,000 | 579,860,000 | 552,779,000 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 661,046,000 | 653,707,000 | 596,742,000 |
S&GA Expenses | 7.6% | 174,024,000 | 161,684,000 | 150,295,000 | 139,945,000 | 136,622,000 | 159,275,000 | 186,347,000 | 287,614,000 | 324,968,000 | 340,528,000 | 354,322,000 | 298,732,000 | 290,321,000 | 293,417,000 | 286,644,000 | 269,427,000 | 278,103,000 | 269,190,000 | 244,622,000 | 224,269,000 | 182,345,000 |
EBITDA | 100.0% | - | -286,018,000 | -235,535,000 | 35,013,000 | -1,953,000 | 20,852,000 | -4,312,000 | -208,291,000 | -156,341,000 | -126,141,000 | -89,562,000 | 130,718,000 | 175,359,000 | 203,257,000 | 387,534,000 | - | - | - | - | - | - |
EBITDA Margin | 100.0% | - | -0.50 | -0.40 | 0.04 | 0.00 | 0.02 | -0.01 | -0.32 | -0.23 | -0.18 | -0.12 | 0.14 | 0.19 | 0.21 | 0.35 | - | - | - | - | - | - |
Interest Expenses | 2.1% | 7,769,000 | 7,608,000 | 8,122,000 | 8,629,000 | 8,830,000 | 9,057,000 | 9,349,000 | 9,545,000 | 9,633,000 | 9,717,000 | 9,510,000 | -15,888,000 | -6,314,000 | 3,047,000 | 12,440,000 | 46,860,000 | 46,140,000 | 45,451,000 | 44,789,000 | 44,119,000 | 43,662,000 |
Earnings Before Taxes | 8.3% | -281,430,000 | -306,857,000 | -257,985,000 | 11,261,000 | -25,803,000 | -3,476,000 | -29,148,000 | -268,633,000 | -216,410,000 | -171,338,000 | -134,552,000 | 110,278,000 | 145,345,000 | 163,882,000 | 338,766,000 | 119,276,000 | 95,846,000 | 56,573,000 | -76,156,000 | -103,253,000 | -89,872,000 |
EBT Margin | 100.0% | - | -0.53 | -0.44 | 0.01 | -0.03 | 0.00 | -0.04 | -0.41 | -0.31 | -0.24 | -0.18 | 0.12 | 0.15 | 0.17 | 0.30 | - | - | - | - | - | - |
Net Income | 6.0% | -309,035,000 | -328,880,000 | -269,722,000 | 7,321,000 | -28,153,000 | -3,893,000 | -28,597,000 | -607,742,000 | -549,743,000 | -494,504,000 | -444,263,000 | 94,684,000 | 145,314,000 | 170,074,000 | 294,145,000 | 429,808,000 | 399,086,000 | 359,604,000 | 273,741,000 | -49,259,000 | -47,311,000 |
Net Income Margin | 100.0% | - | -0.57 | -0.46 | 0.01 | -0.03 | 0.00 | -0.04 | -0.92 | -0.81 | -0.72 | -0.64 | 0.08 | 0.14 | 0.17 | 0.26 | - | - | - | - | - | - |
Free Cashflow | 100.0% | - | -400,200,000 | -290,091,000 | 115,428,000 | 86,502,000 | 40,923,000 | 18,844,000 | -89,513,000 | -52,684,000 | -38,998,000 | 772,000 | 178,114,000 | 171,476,000 | 193,675,000 | 314,815,000 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | 3.0% | 2,971 | 2,885 | 2,534 | 2,422 | 2,456 | 2,519 | 2,612 | 2,415 | 2,497 | 2,249 | 2,390 | 3,096 | 3,079 | 3,091 | 3,233 | 2,895 | 2,878 | 2,836 | 2,668 | 2,248 | 2,247 |
Current Assets | 2.9% | 2,617 | 2,543 | 2,203 | 2,152 | 2,191 | 2,253 | 2,345 | 2,156 | 2,238 | 1,989 | 2,131 | 2,537 | 2,531 | 2,558 | 2,721 | 2,408 | 2,414 | 2,374 | 2,208 | 2,079 | 2,083 |
Cash Equivalents | 37.5% | 425 | 309 | 276 | 315 | 522 | 543 | 869 | 633 | 565 | 414 | 398 | 633 | 530 | 486 | 683 | 248 | 273 | 376 | 279 | 480 | 805 |
Inventory | 15.0% | 26.00 | 22.00 | 22.00 | 21.00 | 20.00 | 24.00 | 25.00 | 23.00 | 24.00 | 22.00 | 22.00 | 22.00 | 24.00 | 23.00 | 18.00 | 19.00 | 19.00 | 11.00 | 9.00 | 8.00 | - |
Net PPE | 7.6% | 92.00 | 85.00 | 74.00 | 181 | 177 | 178 | 178 | 180 | 179 | 180 | 181 | 182 | 173 | 164 | 154 | 149 | 135 | 134 | 132 | 132 | 128 |
Liabilities | 6.0% | 2,543 | 2,399 | 1,961 | 1,828 | 1,831 | 1,810 | 1,840 | 1,884 | 1,914 | 1,568 | 1,646 | 1,489 | 1,484 | 1,521 | 1,549 | 1,397 | 1,421 | 1,448 | 1,481 | 1,408 | 1,430 |
Current Liabilities | 11.1% | 288 | 259 | 312 | 283 | 268 | 228 | 241 | 280 | 294 | 295 | 599 | 245 | 231 | 258 | 273 | 232 | 241 | 252 | 280 | 260 | 249 |
Shareholder's Equity | -12.0% | 428 | 487 | 573 | 594 | 625 | 710 | 772 | 531 | 583 | 681 | 743 | 1,521 | 1,503 | 1,472 | 1,577 | 1,498 | 1,457 | 1,387 | 1,101 | 840 | 817 |
Retained Earnings | -5.5% | -1,639 | -1,553 | -1,429 | -1,377 | -1,330 | -1,225 | -1,159 | -1,384 | -1,302 | -1,221 | -1,131 | -909 | -878 | -846 | -707 | -857 | -883 | -882 | -967 | -1,287 | -1,282 |
Additional Paid-In Capital | 1.4% | 2,118 | 2,089 | 2,060 | 2,035 | 2,009 | 1,983 | 1,964 | 1,942 | 1,910 | 1,926 | 1,896 | 2,312 | 2,272 | 2,234 | 2,204 | 2,219 | 2,177 | 2,118 | 2,047 | 2,030 | 2,012 |
Shares Outstanding | 0.1% | 143 | 143 | 142 | 142 | 142 | 142 | 141 | 141 | 141 | 141 | 140 | 140 | 139 | 139 | 140 | 141 | 140 | 139 | 138 | 137 | 129 |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | 223 | 218 | 210 | 213 | 162 | 188 | 180 | 139 | 130 | 121 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | -21.0% | -455 | -376 | -274 | 130 | 98.00 | 54.00 | 31.00 | -74.91 | -29.61 | -11.18 | 36.00 | 216 | 213 | 230 | 346 | 183 | 170 | 697 | 603 | 508 | 563 |
Share Based Compensation | 2.0% | 103 | 101 | 100 | 97.00 | 104 | 109 | 121 | 193 | 209 | 227 | 230 | 170 | 148 | 142 | 147 | 146 | 156 | 148 | 131 | 120 | 106 |
Cashflow From Investing | 24.2% | -227 | -300 | -262 | -379 | -73.77 | -171 | 195 | 288 | 268 | 448 | 274 | 225 | 124 | -66.11 | -41.27 | -505 | -814 | -1,079 | -929 | -657 | -500 |
Cashflow From Financing | 32.0% | 586 | 444 | -55.29 | -66.77 | -67.14 | 246 | 246 | -213 | -203 | -509 | -596 | -55.90 | -80.01 | -53.94 | 100 | 90.00 | 112 | 530 | 476 | 470 | 610 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | 0.00 | 91.00 | 125 | 125 | 125 | 34.00 | - | - | - | - | - | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenue: | ||||
Revenue | $ 188,411 | $ 133,791 | $ 318,935 | $ 275,710 |
Expenses: | ||||
Cost of sales | 2,537 | 4,745 | 3,880 | 8,914 |
Research, development and patent | 229,927 | 180,758 | 427,740 | 341,884 |
Selling, general and administrative | 46,142 | 33,802 | 91,658 | 67,929 |
Total operating expenses | 278,606 | 219,305 | 523,278 | 418,727 |
Loss from operations | (90,195) | (85,514) | (204,343) | (143,017) |
Other income (expense): | ||||
Investment income | 20,792 | 3,403 | 39,419 | 5,396 |
Interest expense | (2,291) | (2,130) | (3,899) | (4,252) |
Interest expense related to sale of future royalties | (17,655) | 0 | (33,170) | 0 |
Gain (loss) on investments | 718 | (6,337) | 189 | (12,963) |
Other income (expense) | 11,183 | (12,297) | 11,414 | (12,110) |
Loss before income tax expense | (77,448) | (102,875) | (190,390) | (166,946) |
Income tax expense | (7,842) | (2,260) | (19,223) | (3,354) |
Net loss | $ (85,290) | $ (105,135) | $ (209,613) | $ (170,300) |
Basic net loss per share (in dollars per share) | $ (0.6) | $ (0.74) | $ (1.47) | $ (1.2) |
Diluted net loss per share (in dollars per share) | $ (0.6) | $ (0.74) | $ (1.47) | $ (1.2) |
Shares used in computing basic net loss per share (in shares) | 143,098 | 141,794 | 142,918 | 141,697 |
Shares used in computing diluted net loss per share (in shares) | 143,098 | 141,794 | 142,918 | 141,697 |
Commercial Revenue [Member] | ||||
Revenue: | ||||
Revenue | $ 77,897 | $ 78,184 | $ 145,664 | $ 150,468 |
SPINRAZA Royalties [Member] | ||||
Revenue: | ||||
Revenue | 61,012 | 59,627 | 111,258 | 113,444 |
Other Commercial Revenue [Member] | ||||
Revenue: | ||||
Revenue | 16,885 | 18,557 | 34,406 | 37,024 |
Research and Development Revenue [Member] | ||||
Revenue: | ||||
Revenue | 110,514 | 55,607 | 173,271 | 125,242 |
Collaborative Agreement Revenue [Member] | ||||
Revenue: | ||||
Revenue | 91,013 | 38,247 | 129,347 | 88,032 |
Eplontersen Joint Development Revenue [Member] | ||||
Revenue: | ||||
Revenue | $ 19,501 | $ 17,360 | $ 43,924 | $ 37,210 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 424,790 | $ 276,472 |
Short-term investments | 1,960,598 | 1,710,397 |
Contracts receivable | 27,956 | 25,538 |
Inventories | 25,538 | 22,033 |
Other current assets | 177,872 | 168,254 |
Total current assets | 2,616,754 | 2,202,694 |
Property, plant and equipment, net | 91,634 | 74,294 |
Right-of-use assets | 176,718 | 181,544 |
Deposits and other assets | 86,025 | 75,344 |
Total assets | 2,971,131 | 2,533,876 |
Current liabilities: | ||
Accounts payable | 24,021 | 17,921 |
Accrued compensation | 29,322 | 49,178 |
Accrued liabilities | 104,745 | 140,101 |
Income taxes payable | 24,732 | 6,249 |
Current portion of deferred contract revenue | 96,252 | 90,577 |
Other current liabilities | 8,903 | 7,535 |
Total current liabilities | 287,975 | 311,561 |
Long-term deferred contract revenue | 254,398 | 287,768 |
Liability related to sale of future royalties, net | 510,174 | 0 |
Long-term lease liabilities | 175,020 | 178,941 |
Long-term obligations | 16,436 | 15,973 |
Total liabilities | 2,542,830 | 1,960,989 |
Stockholders' equity: | ||
Common stock, $0.001 par value; 300,000,000 shares authorized, 143,167,414 and 142,057,736 shares issued and outstanding at June 30, 2023 (unaudited) and December 31, 2022, respectivel | 143 | 142 |
Additional paid-in capital | 2,118,309 | 2,059,850 |
Accumulated other comprehensive loss | (50,913) | (57,480) |
Accumulated deficit | (1,639,238) | (1,429,625) |
Total stockholders' equity | 428,301 | 572,887 |
Total liabilities and stockholders' equity | 2,971,131 | 2,533,876 |
1.75 Percent Convertible Senior Notes [Member] | ||
Current liabilities: | ||
Convertible senior notes, net | 560,937 | 0 |
0 Percent Convertible Senior Notes [Member] | ||
Current liabilities: | ||
Convertible senior notes, net | 623,809 | 622,242 |
0.125 Percent Convertible Senior Notes [Member] | ||
Current liabilities: | ||
Convertible senior notes, net | $ 114,081 | $ 544,504 |